Compare NNOX & ALPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNOX | ALPS |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | Israel | Malaysia |
| Employees | N/A | N/A |
| Industry | Medical Electronics | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.6M | 66.6M |
| IPO Year | 2019 | 2024 |
| Metric | NNOX | ALPS |
|---|---|---|
| Price | $0.64 | $0.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 57.6K |
| Earning Date | 04-20-2026 | 07-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $147.55 | N/A |
| Revenue Next Year | $81.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.23 |
| 52 Week High | $4.71 | $1.72 |
| Indicator | NNOX | ALPS |
|---|---|---|
| Relative Strength Index (RSI) | 34.95 | 47.93 |
| Support Level | N/A | $0.38 |
| Resistance Level | $0.81 | $0.44 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 6.37 | 39.39 |
Nano X Imaging Ltd is focused on driving the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. The group combines affordable imaging hardware, progressive AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. The three segments are composed of the Nanox.ARC segment, the AI and software solutions segment, and the Radiology services segment. Key revenue is generated from Radiology Services.
ALPS Group Inc is an investment holding company involved in research and development, including stem cell and biotechnology-related business, and investing and managing businesses such as health and beauty centres and medical centres. The Company operates through Medical and Wellness, Life Science and Others segments. Medical and Wellness generates maximum revenue from non-surgical aesthetic services, surgical aesthetic services, medical consultation, health screenings, cellular therapy and research, and COVID-19 testing. Life Science provides whole-genome sequencing and pharmacogenomics, while Others comprises investment holding and provision of management services. The Company generates revenue in Malaysia.